Samuel Singer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2257269/publications.pdf

Version: 2024-02-01

211 papers	37,177 citations	4146 87 h-index	3034 188 g-index
215 all docs	215 docs citations	215 times ranked	29551 citing authors

#	Article	IF	Citations
1	Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. New England Journal of Medicine, 2002, 347, 472-480.	27.0	4,018
2	The landscape of somatic copy-number alteration across human cancers. Nature, 2010, 463, 899-905.	27.8	3,331
3	Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor. Journal of Clinical Oncology, 2003, 21, 4342-4349.	1.6	2,160
4	PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors. Science, 2003, 299, 708-710.	12.6	2,158
5	Differentiation and reversal of malignant changes in colon cancer through PPARÎ³. Nature Medicine, 1998, 4, 1046-1052.	30.7	933
6	Terminal Differentiation of Human Breast Cancer through PPARÎ³. Molecular Cell, 1998, 1, 465-470.	9.7	779
7	Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation. Clinical Cancer Research, 2005, 11, 4182-4190.	7.0	768
8	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell, 2017, 171, 950-965.e28.	28.9	738
9	Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nature Genetics, 2013, 45, 180-185.	21.4	662
10	STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene, 2001, 20, 5054-5058.	5.9	643
11	Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature Genetics, 2010, 42, 715-721.	21.4	642
12	KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors. American Journal of Pathology, 2000, 156, 791-795.	3.8	585
13	Histologic Subtype and Margin of Resection Predict Pattern of Recurrence and Survival for Retroperitoneal Liposarcoma. Annals of Surgery, 2003, 238, 358-371.	4.2	520
14	PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nature Genetics, 2014, 46, 1227-1232.	21.4	472
15	A novel WWTR1â€CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes and Cancer, 2011, 50, 644-653.	2.8	445
16	Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer, 2008, 112, 608-615.	4.1	437
17	Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncology, The, 2009, 10, 1045-1052.	10.7	430
18	Prognostic Value ofKITMutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal Tumors. Journal of Clinical Oncology, 2002, 20, 3898-3905.	1.6	420

#	Article	IF	Citations
19	Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With AdvancedCDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma. Journal of Clinical Oncology, 2013, 31, 2024-2028.	1.6	370
20	Advances in sarcoma genomics and new therapeutic targets. Nature Reviews Cancer, 2011, 11, 541-557.	28.4	364
21	Subtype Specific Prognostic Nomogram for Patients With Primary Liposarcoma of the Retroperitoneum, Extremity, or Trunk. Annals of Surgery, 2006, 244, 381-391.	4.2	331
22	Novel V600E BRAF mutations in imatinibâ€naive and imatinibâ€resistant gastrointestinal stromal tumors. Genes Chromosomes and Cancer, 2008, 47, 853-859.	2.8	329
23	Lessons Learned From the Study of 10,000 Patients With Soft Tissue Sarcoma. Annals of Surgery, 2014, 260, 416-422.	4.2	321
24	High prevalence of CIC fusion with doubleâ€homeobox (DUX4) transcription factors in EWSR1â€negative undifferentiated small blue round cell sarcomas. Genes Chromosomes and Cancer, 2012, 51, 207-218.	2.8	307
25	Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene, 2004, 23, 3999-4006.	5.9	306
26	Consistent MYC and FLT4 gene amplification in radiationâ€induced angiosarcoma but not in other radiationâ€associated atypical vascular lesions. Genes Chromosomes and Cancer, 2011, 50, 25-33.	2.8	291
27	Vaccination With Irradiated, Autologous Melanoma Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor by Adenoviral-Mediated Gene Transfer Augments Antitumor Immunity in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2003, 21, 3343-3350.	1.6	278
28	Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome. American Journal of Surgical Pathology, 2017, 41, 941-949.	3.7	278
29	Identification of a novel, recurrent HEY1â€NCOA2 fusion in mesenchymal chondrosarcoma based on a genomeâ€wide screen of exonâ€level expression data. Genes Chromosomes and Cancer, 2012, 51, 127-139.	2.8	276
30	Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor. Annals of Surgery, 2007, 245, 347-352.	4.2	273
31	Extraskeletal myxoid chondrosarcoma. Cancer, 2008, 113, 3364-3371.	4.1	272
32	PPARÎ³ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. Journal of Clinical Investigation, 2002, 110, 923-932.	8.2	257
33	Prognostic Factors Predictive of Survival for Truncal and Retroperitoneal Soft-Tissue Sarcoma. Annals of Surgery, 1995, 221, 185-195.	4.2	251
34	Do Radiation-Associated Soft Tissue Sarcomas Have the Same Prognosis As Sporadic Soft Tissue Sarcomas?. Journal of Clinical Oncology, 2010, 28, 2064-2069.	1.6	250
35	KDR Activating Mutations in Human Angiosarcomas Are Sensitive to Specific Kinase Inhibitors. Cancer Research, 2009, 69, 7175-7179.	0.9	247
36	Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated WithCDK4Inhibitor Palbociclib. JAMA Oncology, 2016, 2, 937.	7.1	241

#	Article	IF	Citations
37	Histology-based Classification Predicts Pattern of Recurrence and Improves Risk Stratification in Primary Retroperitoneal Sarcoma. Annals of Surgery, 2016, 263, 593-600.	4.2	238
38	Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis. Clinical Cancer Research, 2011, 17, 4082-4090.	7.0	237
39	Surface-enhanced resonance Raman scattering nanostars for high-precision cancer imaging. Science Translational Medicine, 2015, 7, 271ra7.	12.4	236
40	Soft tissue sarcomas of adults: state of the translational science. Clinical Cancer Research, 2003, 9, 1941-56.	7.0	224
41	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	28.9	223
42	A Prognostic Nomogram for Prediction of Recurrence in Desmoid Fibromatosis. Annals of Surgery, 2013, 258, 347-353.	4.2	222
43	Gene Expression Profiling of Liposarcoma Identifies Distinct Biological Types/Subtypes and Potential Therapeutic Targets in Well-Differentiated and Dedifferentiated Liposarcoma. Cancer Research, 2007, 67, 6626-6636.	0.9	217
44	Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Current Opinion in Oncology, 2011, 23, 373-378.	2.4	203
45	Long-Term Outcomes After Function-Sparing Surgery Without Radiotherapy for Soft Tissue Sarcoma of the Extremities and Trunk. Journal of Clinical Oncology, 1999, 17, 3252-3259.	1.6	194
46	Prognostic Factors Predictive of Survival and Local Recurrence for Extremity Soft Tissue Sarcoma. Annals of Surgery, 1994, 219, 165-173.	4.2	192
47	Diagnosis and management of lipomatous tumors. Journal of Surgical Oncology, 2008, 97, 298-313.	1.7	191
48	Chemotherapy Is Associated With Improved Survival in Adult Patients With Primary Extremity Synovial Sarcoma. Annals of Surgery, 2007, 246, 105-113.	4.2	187
49	PPARÎ³ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. Journal of Clinical Investigation, 2002, 110, 923-932.	8.2	185
50	Dichotomy of Genetic Abnormalities in PEComas With Therapeutic Implications. American Journal of Surgical Pathology, 2015, 39, 813-825.	3.7	177
51	Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. Journal of Clinical Investigation, 2007, 117, 3248-3257.	8.2	167
52	Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer, 2010, 116, 2258-2265.	4.1	163
53	A Synovial Sarcoma-Specific Preoperative Nomogram Supports a Survival Benefit to Ifosfamide-Based Chemotherapy and Improves Risk Stratification for Patients. Clinical Cancer Research, 2008, 14, 8191-8197.	7.0	160
54	Laparoscopic Versus Open Gastric Resections for Primary Gastrointestinal Stromal Tumors (GISTs): A Size-Matched Comparison. Annals of Surgical Oncology, 2011, 18, 1599-1605.	1.5	160

#	Article	IF	Citations
55	Management of soft-tissue sarcomas: an overview and update. Lancet Oncology, The, 2000, 1, 75-85.	10.7	157
56	Recurrent CIC Gene Abnormalities in Angiosarcomas. American Journal of Surgical Pathology, 2016, 40, 645-655.	3.7	157
57	A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nature Genetics, 2014, 46, 595-600.	21.4	152
58	Novel ZC3H7Bâ€BCOR, MEAF6â€PHF1, and EPC1â€PHF1 fusions in ossifying fibromyxoid tumorsâ€"molecular characterization shows genetic overlap with endometrial stromal sarcoma. Genes Chromosomes and Cancer, 2014, 53, 183-193.	2.8	145
59	Sorafenib Inhibits the Imatinib-Resistant KIT T670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2007, 13, 4874-4881.	7.0	144
60	Recurrent thromboembolic events after ischemic stroke in patients with cancer. Neurology, 2014, 83, 26-33.	1.1	144
61	Functional Copy-Number Alterations in Cancer. PLoS ONE, 2008, 3, e3179.	2.5	142
62	Gradient, high-resolution, magic angle spinning1H nuclear magnetic resonance spectroscopy of intact cells. Magnetic Resonance in Medicine, 1998, 39, 337-345.	3.0	141
63	Novel MIR143â€NOTCH fusions in benign and malignant glomus tumors. Genes Chromosomes and Cancer, 2013, 52, 1075-1087.	2.8	138
64	Near universal detection of alterations in <scp>CTNNB1</scp> and <scp>Wnt</scp> pathway regulators in desmoidâ€type fibromatosis by wholeâ€exome sequencing and genomic analysis. Genes Chromosomes and Cancer, 2015, 54, 606-615.	2.8	138
65	A Postoperative Nomogram for Local Recurrence Risk in Extremity Soft Tissue Sarcomas After Limb-Sparing Surgery Without Adjuvant Radiation. Annals of Surgery, 2012, 255, 343-347.	4.2	135
66	Response to Chemotherapy and Predictors of Survival in Adult Rhabdomyosarcoma. Annals of Surgery, 2001, 234, 215-223.	4.2	132
67	The Impact of Chemotherapy on the Survival of Patients With High-grade Primary Extremity Liposarcoma. Annals of Surgery, 2004, 240, 686-697.	4.2	132
68	Impact of Intensity-Modulated Radiation Therapy on Local Control in Primary Soft-Tissue Sarcoma of the Extremity. Journal of Clinical Oncology, 2008, 26, 3440-3444.	1.6	132
69	Validation of the postoperative nomogram for 12-year sarcoma-specific mortality. Cancer, 2004, 101, 2270-2275.	4.1	131
70	Predictors of Survival and Recurrence in Primary Leiomyosarcoma. Annals of Surgical Oncology, 2013, 20, 1851-1857.	1.5	128
71	Atypical lipomatous tumor/well-differentiated liposarcoma of the extremity and trunk wall: Importance of histological subtype with treatment recommendations. Annals of Surgical Oncology, 2004, 11, 78-84.	1.5	125
72	Comparison of Local Recurrence With Conventional and Intensity-Modulated Radiation Therapy for Primary Soft-Tissue Sarcomas of the Extremity. Journal of Clinical Oncology, 2014, 32, 3236-3241.	1.6	125

#	Article	IF	Citations
73	Gradient, high-resolution, magic-angle spinning nuclear magnetic resonance spectroscopy of human adipocyte tissue. Magnetic Resonance in Medicine, 1997, 38, 399-403.	3.0	124
74	Adults With Ewingâ€™s Sarcoma/Primitive Neuroectodermal Tumor. Annals of Surgery, 1999, 230, 79.	4.2	123
75	Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material. Genes Chromosomes and Cancer, 2014, 53, 475-486.	2.8	120
76	Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2007, 13, 170-181.	7.0	118
77	Predicting Outcome by Growth Rate of Locally Recurrent Retroperitoneal Liposarcoma. Annals of Surgery, 2009, 250, 977-982.	4.2	114
78	Skeletal Metastases in Myxoid Liposarcoma: An Unusual Pattern of Distant Spread. Annals of Surgical Oncology, 2007, 14, 1507-1514.	1.5	112
79	Frequent Alterations and Epigenetic Silencing of Differentiation Pathway Genes in Structurally Rearranged Liposarcomas. Cancer Discovery, 2011, 1, 587-597.	9.4	108
80	MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. Oncotarget, 2015, 6, 8226-8243.	1.8	107
81	Small RNA Sequencing and Functional Characterization Reveals MicroRNA-143 Tumor Suppressor Activity in Liposarcoma. Cancer Research, 2011, 71, 5659-5669.	0.9	106
82	Outcome of Metastatic GIST in the Era before Tyrosine Kinase Inhibitors. Annals of Surgical Oncology, 2007, 14, 134-142.	1.5	104
83	Oncologic Outcomes of Sporadic, Neurofibromatosis-Associated, and Radiation-Induced Malignant Peripheral Nerve Sheath Tumors. Annals of Surgical Oncology, 2013, 20, 66-72.	1.5	104
84	Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma Identifies CDK4 and IGF1R as Synergistic Drug Targets. Science Signaling, 2013, 6, ra85.	3.6	97
85	The miRâ€17â€92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. Genes Chromosomes and Cancer, 2012, 51, 569-578.	2.8	96
86	Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 319-330.e1.	0.8	96
87	Synovial Sarcoma. Clinical Orthopaedics and Related Research, 2004, 419, 155-161.	1.5	92
88	Classification of human liposarcoma and lipoma using ex vivo proton NMR spectroscopy. Magnetic Resonance in Medicine, 1999, 41, 257-267.	3.0	90
89	Dermatofibrosarcoma protuberans (DFSP): Predictors of Recurrence and the Use of Systemic Therapy. Annals of Surgical Oncology, 2011, 18, 328-336.	1.5	88
90	Posterior Reversible Encephalopathy Syndrome in Patients With Cancer. Oncologist, 2015, 20, 806-811.	3.7	88

#	Article	IF	Citations
91	Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets. Modern Pathology, 2020, 33, 591-602.	5.5	87
92	Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KITAY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug Resistance. Clinical Cancer Research, 2009, 15, 6862-6870.	7.0	86
93	Expression Profiling of Liposarcoma Yields a Multigene Predictor of Patient Outcome and Identifies Genes That Contribute to Liposarcomagenesis. Cancer Research, 2011, 71, 2697-2705.	0.9	86
94	The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial. Clinical Cancer Research, 2012, 18, 2638-2647.	7.0	85
95	Extraskeletal myxoid chondrosarcoma with nonâ€“EWSR1-NR4A3 variant fusions correlate with rhabdoid phenotype and high-grade morphology. Human Pathology, 2014, 45, 1084-1091.	2.0	83
96	Cryptogenic Subtype Predicts Reduced Survival Among Cancer Patients With Ischemic Stroke. Stroke, 2014, 45, 2292-2297.	2.0	80
97	Spindle Cell Rhabdomyosarcoma (So-Called) in Adults. American Journal of Surgical Pathology, 1998, 22, 459-464.	3.7	79
98	IGF2 overâ€expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting. Journal of Pathology, 2010, 221, 300-307.	4.5	78
99	Distant metastasis in retroperitoneal dedifferentiated liposarcoma is rare and rapidly fatal: a clinicopathological study with emphasis on the low-grade myxofibrosarcoma-like pattern as an early sign of dedifferentiation. Modern Pathology, 2005, 18, 976-984.	5.5	73
100	Evaluation of a Clinically Applicable Post-Surgical Classification System for Primary Retroperitoneal Soft-Tissue Sarcoma. Annals of Surgical Oncology, 2004, 11, 483-490.	1.5	72
101	Prognostic Factors for Survival in Patients With Locally Recurrent Extremity Soft Tissue Sarcomas. Annals of Surgical Oncology, 2005, 12, 228-236.	1.5	71
102	Flavopiridol Targets c-KIT Transcription and Induces Apoptosis in Gastrointestinal Stromal Tumor Cells. Cancer Research, 2006, 66, 5858-5866.	0.9	70
103	Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. Molecular Cancer Therapeutics, 2008, 7, 890-896.	4.1	70
104	GLI1-amplifications expand the spectrum of soft tissue neoplasms defined by GLI1 gene fusions. Modern Pathology, 2019, 32, 1617-1626.	5.5	70
105	Size and Location are the Most Important Risk Factors for Malignant Behavior in Resected Solitary Fibrous Tumors. Annals of Surgical Oncology, 2017, 24, 3865-3871.	1.5	69
106	Adult Rhabdomyosarcoma Survival Improved With Treatment on Multimodality Protocols. International Journal of Radiation Oncology Biology Physics, 2013, 86, 58-63.	0.8	68
107	Local control comparison of adjuvant brachytherapy to intensityâ€modulated radiotherapy in primary highâ€grade sarcoma of the extremity. Cancer, 2011, 117, 3229-3234.	4.1	67
108	A Developmental Model of Sarcomagenesis Defines a Differentiation-Based Classification for Liposarcomas. American Journal of Pathology, 2008, 172, 1069-1080.	3.8	65

#	Article	IF	Citations
109	Why Do Patients with Low-Grade Soft Tissue Sarcoma Die?. Annals of Surgical Oncology, 2008, 15, 3550-3560.	1.5	64
110	Blood Neutrophil-to-Lymphocyte Ratio is Prognostic in Gastrointestinal Stromal Tumor. Annals of Surgical Oncology, 2013, 20, 593-599.	1.5	64
111	Comparison of Perioperative Radiation Therapy and Surgery Versus Surgery Alone in 204 Patients With Primary Retroperitoneal Sarcoma. Annals of Surgery, 2015, 262, 156-162.	4.2	64
112	Intensity Modulated Radiation Therapy for Primary Soft Tissue Sarcoma of the Extremity: Preliminary Results. International Journal of Radiation Oncology Biology Physics, 2007, 68, 458-464.	0.8	63
113	Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nature Communications, 2022, 13, .	12.8	63
114	Influence of site on the therapeutic ratio of adjuvant radiotherapy in soft-tissue sarcoma of the extremity. International Journal of Radiation Oncology Biology Physics, 2005, 63, 202-208.	0.8	62
115	Integrin-Î±10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma. Cancer Discovery, 2016, 6, 1148-1165.	9.4	62
116	Copy Number Losses Define Subgroups of Dedifferentiated Liposarcoma with Poor Prognosis and Genomic Instability. Clinical Cancer Research, 2012, 18, 1334-1340.	7.0	59
117	ATRX is a regulator of therapy induced senescence in human cells. Nature Communications, 2017, 8, 386.	12.8	59
118	Long-term Salvageability for Patients With Locally Recurrent Soft-Tissue Sarcomas. Archives of Surgery, 1992, 127, 548.	2.2	58
119	The enigma of myxofibrosarcoma of the extremity. Cancer, 2012, 118, 518-527.	4.1	58
120	Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors. Annals of Surgery, 2018, 268, 296-302.	4.2	58
121	Angiogenic Profile of Soft Tissue Sarcomas Based on Analysis of Circulating Factors and Microarray Gene Expression. Journal of Surgical Research, 2006, 135, 282-290.	1.6	57
122	Biochemical Analysis Using High-Resolution Magic Angle Spinning NMR Spectroscopy Distinguishes Lipoma-Like Well-Differentiated Liposarcoma from Normal Fat. Journal of the American Chemical Society, 2001, 123, 9200-9201.	13.7	54
123	SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors. BMC Cancer, 2012, 12, 408.	2.6	54
124	Toward Better Soft Tissue Sarcoma Staging: Building on American Joint Committee on Cancer Staging Systems Versions 6 and 7. Annals of Surgical Oncology, 2013, 20, 3377-3383.	1.5	52
125	Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nature Communications, 2022, 13, .	12.8	51
126	Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic softâ€tissue sarcoma of the extremity. Cancer, 2007, 110, 2050-2060.	4.1	50

#	Article	IF	Citations
127	miR-193bâ€“Regulated Signaling Networks Serve as Tumor Suppressors in Liposarcoma and Promote Adipogenesis in Adipose-Derived Stem Cells. Cancer Research, 2017, 77, 5728-5740.	0.9	50
128	High-resolution MAS NMR spectroscopy detection of the spin magnetization exchange by cross-relaxation and chemical exchange in intact cell lines and human tissue specimens. Magnetic Resonance in Medicine, 2006, 55, 1246-1256.	3.0	45
129	Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma.. Journal of Clinical Oncology, 2019, 37, 11004-11004.	1.6	44
130	Influence of compartmental involvement on the patterns of morbidity in soft tissue sarcoma of the thigh. Cancer, 2009, 115, 149-157.	4.1	43
131	Synovial sarcoma: the importance of size and location for survival. Clinical Orthopaedics and Related Research, 2004, , 155-61.	1.5	43
132	ZIC1 Overexpression Is Oncogenic in Liposarcoma. Cancer Research, 2010, 70, 6891-6901.	0.9	41
133	Multiple primary soft tissue sarcomas. Cancer, 2004, 101, 2633-2635.	4.1	40
134	Association of MRI T2 Signal Intensity With Desmoid Tumor Progression During Active Observation. Annals of Surgery, 2020, 271, 748-755.	4.2	40
135	Pediatric and Adolescent Synovial Sarcoma: Multivariate Analysis of Prognostic Factors and Survival Outcomes. Annals of Surgical Oncology, 2013, 20, 73-79.	1.5	38
136	Targeted exome sequencing profiles genetic alterations in leiomyosarcoma. Genes Chromosomes and Cancer, 2016, 55, 124-130.	2.8	38
137	PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence. Oncogene, 2018, 37, 5066-5078.	5.9	38
138	Longâ€term outcomes in extremity soft tissue sarcoma after a pathologically negative reâ€resection and without radiotherapy. Cancer, 2008, 112, 2774-2779.	4.1	35
139	A Differentiation-Based Phylogeny of Cancer Subtypes. PLoS Computational Biology, 2010, 6, e1000777.	3.2	34
140	Biochemical correlates of thiazolidinedione-induced adipocyte differentiation by high-resolution magic angle spinning NMR spectroscopy. Magnetic Resonance in Medicine, 2002, 48, 602-610.	3.0	33
141	Optimal Percent Myxoid Component to Predict Outcome in High-Grade Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma. Annals of Surgical Oncology, 2016, 23, 818-825.	1.5	33
142	A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. Investigational New Drugs, 2019, 37, 282-290.	2.6	32
143	mRNA and protein levels of FUS, EWSR1, and TAF15 are upregulated in liposarcoma. Genes Chromosomes and Cancer, 2011, 50, 338-347.	2.8	31
144	Water suppression without signal loss in HR-MAS 1H NMR of cells and tissues. Journal of Magnetic Resonance, 2004, 171, 143-150.	2.1	30

#	Article	IF	Citations
145	Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma. Cancer Research, 2016, 76, 6095-6106.	0.9	30
146	BCOR upregulation in a poorly differentiated synovial sarcoma with SS18L1â€“SSX1 fusionâ€”A pathologic and molecular pitfall. Genes Chromosomes and Cancer, 2017, 56, 296-302.	2.8	30
147	New diagnostic modalities in soft tissue sarcoma. , 1999, 17, 11-22.		29
148	Effectiveness of Palliative Procedures for Intra-Abdominal Sarcomas. Annals of Surgical Oncology, 2005, 12, 1084-1089.	1.5	29
149	Novel oncogene and tumor suppressor mutations in KIT and PDGFRA wild type gastrointestinal stromal tumors revealed by next generation sequencing. Genes Chromosomes and Cancer, 2015, 54, 177-184.	2.8	28
150	Isotropic susceptibility shift under MAS: The origin of the split water resonances in1H MAS NMR spectra of cell suspensions. Magnetic Resonance in Medicine, 2003, 50, 515-521.	3.0	26
151	A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas. Oncologist, 2015, 20, 1245-1246.	3.7	25
152	Translocation t(8;13)(p11;q11-12) in stem cell leukemia/lymphoma of t-cell and myeloid lineages. Genes Chromosomes and Cancer, 1995, 12, 148-151.	2.8	23
153	Restoration of C/EBPÎ± in dedifferentiated liposarcoma induces G2/M cell cycle arrest and apoptosis. Genes Chromosomes and Cancer, 2012, 51, 313-327.	2.8	22
154	Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival. Cancer Research, 2020, 80, 2461-2471.	0.9	22
155	Correlation of lipid content and composition with liposarcoma histology and grade. Annals of Surgical Oncology, 1997, 4, 557-563.	1.5	20
156	miR-193b regulates tumorigenesis in liposarcoma cells via PDGFR, TGFÎ², and Wnt signaling. Scientific Reports, 2019, 9, 3197.	3.3	20
157	Femoral Fracture in Primary Soft-Tissue Sarcoma of the Thigh and Groin Treated with Intensity-Modulated Radiation Therapy: Observed versus Expected Risk. Annals of Surgical Oncology, 2019, 26, 1326-1331.	1.5	20
158	Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center. , 2022, 10, e004149.		20
159	Soft tissue sarcoma of the head & neck: Nomogram validation and analysis of staging systems. Journal of Surgical Oncology, 2015, 111, 690-695.	1.7	19
160	Single-Stage, Multimodality Treatment of Soft-Tissue Sarcoma of the Extremity. Annals of Plastic Surgery, 1997, 39, 454-460.	0.9	18
161	Application of Molecular Biology to Individualize Therapy for Patients with Liposarcoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 213-218.	3.8	18
162	Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes. JCO Precision Oncology, 2020, 4, 1350-1360.	3.0	18

#	Article	IF	Citations
163	Prognostic Factors and Survival in Pediatric and Adolescent Liposarcoma. Sarcoma, 2012, 2012, 1-6.	1.3	17
164	CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers. Genes Chromosomes and Cancer, 2012, 51, 186-195.	2.8	17
165	Percutaneous Cryoablation Provides Disease Control for Extra-Abdominal Desmoid-Type Fibromatosis Comparable with Surgical Resection. Annals of Surgical Oncology, 2022, 29, 640-648.	1.5	17
166	Resolution of creatine and phosphocreatine ¹H signals in isolated human skeletal muscle using HRâ€MAS ¹H NMR. Magnetic Resonance in Medicine, 2008, 59, 1221-1224.	3.0	16
167	Fat-free MRI based on magnetization exchange. Magnetic Resonance in Medicine, 2010, 63, 713-718.	3.0	16
168	Liposarcoma subtypes: identification with computed tomography and ultrasound-guided percutaneous needle biopsy. European Radiology, 2005, 15, 383-389.	4.5	15
169	Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma. , 1999, 86, 1621-1627.		13
170	Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. Journal of Clinical Oncology, 2022, 40, 997-1008.	1.6	13
171	Comprehensive genomic profiling of EWSR1/FUS::CREB translocation-associated tumors uncovers prognostically significant recurrent genetic alterations and methylation-transcriptional correlates. Modern Pathology, 2022, 35, 1055-1065.	5.5	13
172	Reconstruction After Soft Tissue Sarcoma Resection in the Setting of Brachytherapy. Annals of Plastic Surgery, 2004, 52, 486-491.	0.9	12
173	Yield of Colonoscopy in Identification of Newly Diagnosed Desmoid-Type Fibromatosis with Underlying Familial Adenomatous Polyposis. Annals of Surgical Oncology, 2019, 26, 765-771.	1.5	12
174	A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma.. Journal of Clinical Oncology, 2019, 37, 11049-11049.	1.6	12
175	Histologic Subtype Defines the Risk and Kinetics of Recurrence and Death for Primary Extremity/Truncal Liposarcoma. Annals of Surgery, 2021, 273, 1189-1196.	4.2	11
176	A phase II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with untreated advanced gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2020, 38, 11508-11508.	1.6	10
177	Patterns of deregulation of insulin growth factor signalling pathway in paediatric and adult gastrointestinal stromal tumours. European Journal of Cancer, 2012, 48, 3215-3222.	2.8	9
178	High-Resolution Magic Angle Spinning NMR Spectroscopy. , 2007, , 113-147.		8
179	SKP2 Activation by Thyroid Hormone Receptor Î²2 Bypasses Rb-Dependent Proliferation in Rb-Deficient Cells. Cancer Research, 2017, 77, 6838-6850.	0.9	8
180	Statistical Assessment of Depth Normalization for Small RNA Sequencing. JCO Clinical Cancer Informatics, 2020, 4, 567-582.	2.1	8

#	Article	IF	Citations
181	Proton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot. Cancer Medicine, 2021, 10, 4221-4227.	2.8	8
182	A phase 1b study of avelumab plus DCC-3014, a potent and selective inhibitor of colony stimulating factor 1 receptor (CSF1R), in patients with advanced high-grade sarcoma.. Journal of Clinical Oncology, 2021, 39, 11549-11549.	1.6	7
183	An Empirical Evaluation of normalization Methods for MicroRNA Arrays in a Liposarcoma Study. Cancer Informatics, 2013, 12, CIN.S11384.	1.9	6
184	A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with metastatic sarcoma.. Journal of Clinical Oncology, 2018, 36, 11516-11516.	1.6	6
185	Empirical insights into the stochasticity of small RNA sequencing. Scientific Reports, 2016, 6, 24061.	3.3	5
186	Activity of sorafenib in radiation-associated breast angiosarcomas harboring MYC and FLT4 amplifications.. Journal of Clinical Oncology, 2012, 30, 10019-10019.	1.6	5
187	Soft tissue sarcoma diagnosed subsequent to lymphoma is associated with prior radiotherapy and decreased survival. Cancer, 2011, 117, 4756-4763.	4.1	4
188	A High-Content Screen for C/EBPÎ± Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma. Clinical Cancer Research, 2022, 28, 175-186.	7.0	4
189	<scp>FGFR2</scp>::<scp>TACC2</scp> fusion as a novel <scp>KIT</scp>â€independent mechanism of targeted therapy failure in a multidrugâ€resistant gastrointestinal stromal tumor. Genes Chromosomes and Cancer, 2022, 61, 412-419.	2.8	4
190	Chromatographic and Electrophoretic Separations Combined with Mass Spectrometry for Metabonomics. , 2007, , 149-169.		3
191	Preclinical study of treatment response in HCTâ€116 cells and xenografts with ¹Hâ€decoupled ³¹P MRS. NMR in Biomedicine, 2011, 24, 1159-1168.	2.8	3
192	Treatment Recommendations for Retroperitoneal Liposarcoma. International Journal of Radiation Oncology Biology Physics, 2017, 98, 271.	0.8	3
193	Femoral Fracture in Primary Soft Tissue Sarcoma Treated with Intensity-Modulated Radiation Therapy with and Without Dose Constraints. Annals of Surgical Oncology, 2021, 28, 2700-2704.	1.5	3
194	The clinical impact of performing routine next generation sequencing (NGS) in gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology, 2017, 35, 11010-11010.	1.6	3
195	Integrin-alpha10 drives tumorigenesis in sarcoma. Oncoscience, 2017, 4, 31-32.	2.2	3
196	Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2022, 28, 1507-1517.	7.0	3
197	SURGICAL MANAGEMENT OF SOFT TISSUE SARCOMA: HISTOLOGIC TYPE AND GRADE GUIDE SURGICAL PLANNING AND INTEGRATION OF MULTIMODALITY THERAPY. , 2010, , 1057-1069.		2
198	The Oncolytic Activity of Myxoma Virus against Soft Tissue Sarcoma Is Mediated by the Overexpression of Ribonucleotide Reductase. Clinical Medicine Insights: Oncology, 2021, 15, 117955492199306.	1.3	2

#	Article	IF	Citations
199	Lowâ€grade endometrial stromal sarcomaâ€like tumors in male with <scp>JAZF1</scp> gene fusions. Genes Chromosomes and Cancer, 2022, 61, 63-70.	2.8	2
200	Soft Tissue Sarcomas. , 2012, , 768-782.		2
201	Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). , 0, .		1
202	Enhanced PAtient Clinical Streamlining (EPACS): Quality Initiative to Improve Healthcare for New Surgical Outpatient Visits. Annals of Surgical Oncology, 2022, 29, 1789-1796.	1.5	1
203	Feasibility of Preoperative Dose-Painting Intensity Modulated Radiation Therapy (IMRT) for Borderline-Resectable Primary Retroperitoneal Sarcoma. Annals of Surgical Oncology, 0, , .	1.5	1
204	A tribute to Murray F. Brennan, MD. Journal of Surgical Oncology, 2008, 97, 297-297.	1.7	0
205	Radiation Therapy in Primary Soft Tissue Sarcoma of the Superficial Trunk. Annals of Surgical Oncology, 2021, , 1.	1.5	0
206	How well do we communicate risk? An evaluation of AJCC version 6 and 7 staging systems for soft tissue sarcomas.. Journal of Clinical Oncology, 2012, 30, 10001-10001.	1.6	0
207	Poor prognostic features in angiosarcoma: A single institution retrospective study of 324 patients.. Journal of Clinical Oncology, 2013, 31, 10580-10580.	1.6	0
208	Association of perioperative radiation therapy with outcome in 204 patients with primary retroperitoneal sarcoma: A two-institution study.. Journal of Clinical Oncology, 2013, 31, 10520-10520.	1.6	0
209	A phase Ib study of BGJ398 in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2017, 35, 11039-11039.	1.6	0
210	ASO Visual Abstract: Enhanced PAtient Clinical Streamlining (EPACS)â€”Quality Initiative to Improve Healthcare for New Surgical Outpatient Visits. Annals of Surgical Oncology, 2022, 29, 1805-1806.	1.5	0
211	Presence of immune infiltrates, increased expression of transposable elements, and viral response pathways in sarcoma associate with response to checkpoint inhibition.. Journal of Clinical Oncology, 2022, 40, 11510-11510.	1.6	0